Naltrexone pharmacokinetics

Goldstein A Brown BW (2003). Urine testing in methadone maintenance treatment applications and limitations. Journal of Substance Abuse Treatment, 25, 61-3 Gonzalez JP Brogden RN (1988). Naltrexone a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35, 192-213... 

Miotto K, McCann M, Basch J, Rawson R ling W (2002). Naltrexone and dysphoria fact or myth American Journal of Addictions, 11, 151-60 Mitchell TB, White JM, Somogyi AA Bodmer F (2003). Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence, 11, 85-94 Mitchell TB, White JM, Somogyi AA Bochner F (2004). Slow-release oral morphine versus methadone a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction, 99, 940-5 Mitka M (2003). Office-based primary care physicians called on to treat the new addict. Journal of the American Medical Association, 290, 735-6... 

Pharmacokinetic properties Naltrexone (Misra, 1981) is absorbed from the gastrointestinal tract, but is subject to considerable first-pass metabolism in the liver, yielding the active metabolite 6-beta-naltrexole. Naltrexone has low plasma binding of about 20%. The half-life of naltrexone is -3 h and of 6-beta-naltrexole is -13 h. 

Misra, A.L. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone, NIDA Res. Monogr. 1981, 28, 132-146. 

Swift R, Davidson D, Rosen S, Fitz E, Camara P. Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. Psychopharmacology (Berl) 1998 135(3) 256-62. 

Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988 35 192-213. 

Naltrexone modestly increases the rate and extent of acamprosate absorption. There is no pharmacokinetic interaction between acamprosate and alcohol or diazepam. Disulflram does not alter the pharmacokinetics of acamprosate, and acamprosate does not alter the pharmacokinetics of imipramine. The combination of acamprosate and barbiturates, meprobamate, or oxazepam does not appear to increase the risk of adverse effects. 

Mason BJ, Goodman AM, Dixon RM, Hameed MHA, Hulot T, Wesnes K, Hunter JA, Boye-son MG. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. (2002) 27, 596-606. 

---